Results 121 to 130 of about 1,800 (153)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy

Frontiers in Cellular and Infection Microbiology, 2021
Wang Zhengtao, Dou Wei
exaly  

Whither Irinotecan?

Journal of Clinical Oncology, 2005
openaire   +2 more sources

Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs

Cancer Science, 2022
Hironobu Minami, Gérard Milano
exaly  

Irinotecan

Reactions Weekly, 2003
openaire   +3 more sources

Irinotecan

Reactions Weekly, 2005
openaire   +1 more source

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)

Annals of Oncology, 2015
M Kochi, Y Kakeji, N Matsuhashi
exaly  

Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview

International Journal of Molecular Sciences, 2020
Beata Marciniak, Mateusz Kciuk, Renata Kontek   +2 more
exaly  

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study

Annals of Oncology, 2009
C Louvet, G Lledo, M Mabro
exaly  

Irinotecan

Reactions Weekly, 2008
openaire   +1 more source

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study

Annals of Oncology, 2007
David Cunningham, Tamás Hickish, Richard H Osborne   +2 more
exaly